DirectMeds vs Hers Canada (2026): GLP-1 Options for Canadian Women

Women approaching GLP-1 treatment face considerations that are not always front-of-mind on general pharmacy platforms: hormonal interactions, polycystic ovary syndrome comorbidities, contraception compatibility, and the particular metabolic profile that distinguishes female patients from male ones during titration. How a platform accounts for those considerations - or doesn't - matters when choosing where to start.

DirectMeds and Hers Canada both facilitate GLP-1 prescriptions for women, but they do so from distinctly different starting points. DirectMeds is a licensed Canadian pharmacy that treats GLP-1 medications as one category within a broad formulary. Hers is a women's health brand that launched GLP-1 weight management as a natural extension of its existing clinical infrastructure for birth control, skincare, and hair treatments. Understanding what each platform was built to do reveals which is the better fit for your circumstances.

Platform Overview

Core Model Differences

DirectMeds was built as a dispensing platform with clinical capability layered on top. Its core competency is getting licensed medications to patients reliably, at competitive prices, with pharmacist support. When GLP-1 medications became a significant category, DirectMeds added the ability to connect patients with physicians for consultations - but the pharmacy relationship remains primary. The platform is gender-neutral by design: it serves anyone in Canada who needs a prescription filled.

Hers was built for women first. The platform launched with hormonal birth control and expanded into hair loss, skincare, anxiety support, and sleep before adding GLP-1 weight management. That trajectory matters because it shaped the clinical team, the intake questionnaire design, and the framing of treatment goals. When a Hers patient begins a GLP-1 program, she is entering an environment where the clinical staff is accustomed to thinking about female metabolic health rather than treating weight management as a gender-neutral biochemistry problem.

For women who want their GLP-1 treatment integrated into a broader understanding of their health - particularly if they are also managing contraception, hormonal shifts, or women-specific skin and hair conditions - Hers offers a cohesion that DirectMeds does not. For women who want a transparent pharmacy relationship with national coverage and no lifestyle-brand overhead, DirectMeds is more direct.

Pricing Breakdown

Province Coverage

DirectMeds ships to all ten Canadian provinces as a licensed national pharmacy. Patients in Quebec and New Brunswick - provinces that some telehealth-first platforms avoid due to regulatory complexity - can order through DirectMeds without restriction.

Hers Canada currently does not serve Quebec or New Brunswick. The exclusion appears to reflect the same combination of physician licensing constraints and operational complexity that affects other US-origin telehealth brands expanding into Canada. Women in those provinces will need to seek alternatives.

Women-Specific Clinical Support

This is where the comparison tilts most clearly in Hers's favour. GLP-1 medications interact with hormonal contraceptives - specifically, rapid weight loss can alter the efficacy of some oral contraceptives, and nausea-induced vomiting in early titration can compromise pill absorption. A clinical team accustomed to managing women's reproductive health is better positioned to flag those interactions proactively than a general pharmacist fielding an isolated GLP-1 query.

Hers's intake questionnaire is designed with women's health context built in. It asks about menstrual cycle regularity, PCOS history, current contraceptive use, and hormonal medication. Those answers shape the clinical review. Women with PCOS - for whom GLP-1 medications are particularly well-evidenced, given the relationship between insulin resistance and androgen excess - receive clinical framing that acknowledges their specific metabolic context rather than a generic weight management protocol.

DirectMeds does not offer women-specific clinical framing. Its pharmacist counselling is competent and thorough within its scope, but it is not structured around the intersections between weight management, hormonal health, and reproductive medicine that are relevant to many women starting GLP-1 treatment.

Patients With Existing Prescriptions

A meaningful proportion of women starting GLP-1 treatment already have a prescription from their family physician or specialist. For those patients, the clinical intake process is redundant - they do not need to establish a new clinical relationship, they need a reliable pharmacy to fill and ship their medication.

DirectMeds excels in this scenario. It accepts prescriptions written by external physicians, processes them efficiently, and ships to all provinces. The pharmacist team is available to answer questions about the medication without requiring a new physician consultation. For a woman who already has a family doctor managing her GLP-1 program, DirectMeds is a straightforward dispensing solution.

Hers requires its own intake and prescribing process. It does not accept external prescriptions, which means a patient with an existing prescription from their family doctor would need to complete the Hers intake and effectively transfer their care to the Hers clinical pathway. That is not necessarily a disadvantage - the Hers clinical team may provide better ongoing monitoring - but it is an additional step that patients with established prescriptions should account for.

Product Ecosystem

Hers Canada's value proposition extends beyond weight management for women who also want to address hair thinning, skin concerns, or contraception through the same platform. Weight changes during GLP-1 treatment can affect hair density, and some women experience changes in skin quality during rapid weight loss. Having a platform that can address those downstream effects without requiring a separate clinical relationship represents genuine convenience.

DirectMeds' formulary breadth is different but similarly relevant. As a full pharmacy, it can fill virtually any Canadian prescription - meaning a woman managing thyroid medication, blood pressure treatment, and a GLP-1 program simultaneously can consolidate all three fills with one provider. That kind of pharmaceutical breadth, paired with a pharmacist who has visibility across a patient's full medication list, has real clinical value in terms of interaction screening.

Pros and Cons

Verdict for Women

For women starting a GLP-1 program with no existing prescription, particularly those with PCOS, who are managing hormonal contraception, or who want a platform that understands women's metabolic health as an integrated subject rather than isolated weight management, Hers Canada is the stronger clinical choice - provided you are in one of the eight provinces it serves.

For women in Quebec or New Brunswick, the choice is straightforward: only DirectMeds of the two covers your province. The same applies to women who already hold a prescription from a family physician and simply want a reliable, transparent pharmacy: DirectMeds handles that role well, with upfront pricing and national reach.

Women managing multiple medications alongside their GLP-1 program may also prefer DirectMeds for the pharmacist-led drug interaction oversight that a full-formulary pharmacy provides. The clinical depth of Hers is more relevant at the prescribing and monitoring stage; the breadth of DirectMeds becomes more useful when the full picture of a patient's pharmacy needs is considered.

Sponsored links above. WeightLossInjections.ca may earn a commission if you purchase through the DirectMeds link at no additional cost to you. All editorial opinions are independent. GLP-1 medications require a valid prescription from a licensed Canadian physician.